ArticleCommunications medicine2025
Hematologic and solid-organ malignancy risk in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune disease characterized by small- and medium-vessel inflammation. Although chronic immune dysregulation and cytotoxic therapy exposure have been hypothesized to increase malignancy risk, large-scale, real-world evidence quantifying these risks has been limited. This study aimed to characterize hematologic and solid-organ malignancy risk profiles in patients with AAV using a large, multi-institutional database.
methodsWe conducted a retrospective cohort study using the TriNetX Research Network, using de-identified electronic medical record data from 2014 to 2024. We identified 19,238 patients with AAV and performed 1:1 propensity score matching to seborrheic keratosis controls on demographic and clinical covariates, yielding 18,255 matched pairs. Five-year incidences of hematologic and solid-organ malignancies were compared using hazard ratios (HR) and 95% confidence intervals (95% CI) from Cox proportional hazards regressions.
resultsHere we show that patients with AAV have a significantly increased risk of overall cancer (HR 1.23; 95% CI 1.12-1.35), driven by higher rates of hematologic malignancies (HR 2.12; 95% CI 1.77-2.53) and specific solid-organ cancers including lung (HR 1.78), bladder (HR 1.99), brain (HR 2.22), and lip/oral cavity/pharyngeal cancers (HR 1.78). Myelodysplastic syndromes (HR 4.11) and leukemia (HR 2.72) show the strongest associations. Negative controls show no risk elevation.
conclusionsPatients with AAV face distinct and heightened risks for select hematologic and solid-organ malignancies, supporting the need for tailored cancer surveillance strategies. These findings provide a large-scale, real-world evidence base for malignancy risk stratification and proactive screening in AAV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.